{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T12:54:54Z","timestamp":1764161694622,"version":"3.46.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"DOI":"10.7759\/cureus.97847","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T12:50:08Z","timestamp":1764161408000},"source":"Crossref","is-referenced-by-count":0,"title":["How to Safely Deliver Stereotactic Ablative Radiotherapy With High-Dose or Multi-agent Systemic Therapy"],"prefix":"10.7759","author":[{"given":"Mark E","family":"Bernard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki Y","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, et al.. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022, 386:449-62. 10.1056\/NEJMoa2111380","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian YY","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, et al.. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023, 402:2197-208. 10.1016\/S0140-6736(23)02033-0","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21037\/tau-19-624","article-title":"Metastasectomy of oligometastatic urothelial cancer: a single-center experience","volume":"9","author":"Muilwijk T","year":"2020","unstructured":"Muilwijk T, Akand M, Van der Aa F, et al.. Metastasectomy of oligometastatic urothelial cancer: a single-center experience. Transl Androl Urol. 2020, 9:1296-305. 10.21037\/tau-19-624","journal-title":"Transl Androl Urol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma DA","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, et al.. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020, 38:2830-8. 10.1200\/JCO.20.00818","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01857-3","article-title":"Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study","volume":"403","author":"Tsai CJ","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N, et al.. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024, 403:171-82. 10.1016\/S0140-6736(23)01857-3","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2024.10.017","article-title":"Microwave ablation of refractory oligometastatic non-small cell lung cancer in the liver","volume":"36","author":"Geevarghese R","year":"2025","unstructured":"Geevarghese R, Kunin H, Petre EN, et al.. Microwave ablation of refractory oligometastatic non-small cell lung cancer in the liver. J Vasc Interv Radiol. 2025, 36:266-73. 10.1016\/j.jvir.2024.10.017","journal-title":"J Vasc Interv Radiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000118","article-title":"Stereotactic body radiation therapy (SBRT) combined with chemotherapy for unresected pancreatic adenocarcinoma","volume":"40","author":"Gurka MK","year":"2017","unstructured":"Gurka MK, Kim C, He AR, et al.. Stereotactic body radiation therapy (SBRT) combined with chemotherapy for unresected pancreatic adenocarcinoma. Am J Clin Oncol. 2017, 40:152-7. 10.1097\/COC.0000000000000118","journal-title":"Am J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00126","article-title":"Phase I trial of carboplatin and gemcitabine chemotherapy and stereotactic ablative radiosurgery for the palliative treatment of persistent or recurrent gynecologic cancer","volume":"5","author":"Kunos CA","year":"2015","unstructured":"Kunos CA, Sherertz TM, Mislmani M, et al.. Phase I trial of carboplatin and gemcitabine chemotherapy and stereotactic ablative radiosurgery for the palliative treatment of persistent or recurrent gynecologic cancer. Front Oncol. 2015, 5:126. 10.3389\/fonc.2015.00126","journal-title":"Front Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez A","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021, 112:90-2. 10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr (Engl Ed)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/434886-how-to-safely-deliver-stereotactic-ablative-radiotherapy-with-high-dose-or-multi-agent-systemic-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T12:50:08Z","timestamp":1764161408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/434886-how-to-safely-deliver-stereotactic-ablative-radiotherapy-with-high-dose-or-multi-agent-systemic-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.97847","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}